(Informaci\u00f3n remitida por la empresa firmante)<\/p>\n
\n\u2022 Gr\u00fcnenthal announces that it agreed to acquire the commercial rights to Cialis* from Eli Lilly and Company in Mexico, Brazil and Colombia, further strengthening Gr\u00fcnenthal’s footprint in Latin America. <\/p>\n
\n\u2022 As part of the acquisition, Gr\u00fcnenthal will transfer the manufacturing of Cialis* to its production site in Chile. <\/p>\n
\n\u2022 Since 2017, Gr\u00fcnenthal has invested more than \u20ac2 billion in successful M&A transactions, significantly strengthening its profitability.<\/p>\n
\nNEWS AKTUELL \/\/ Aachen, Germany, 2 June 2025 \u2013 Gr\u00fcnenthal today announced the acquisition of the commercial rights to Cialis* (tadalafil) in Mexico, Brazil and Colombia from Eli Lilly and Company. Over the next few years, Gr\u00fcnenthal and Lilly will work together to transfer the manufacturing to Gr\u00fcnenthal’s production site in Santiago, Chile, that will supply Cialis* for Mexico, Brazil and Colombia moving forward. The transaction is expected to close in the third quarter of 2025, subject to the satisfaction of customary closing conditions. Gr\u00fcnenthal will finance the transaction using available liquidity. The financial terms of the transaction are not disclosed.<\/p>\n
\nCialis* is indicated for the oral treatment of erectile dysfunction and signs and symptoms of benign prostatic hyperplasia in adult men . The acquisition will expand Gr\u00fcnenthal’s Latin American Men’s Health product portfolio. <\/p>\n
\u00abExecuting on our strategy of targeted acquisitions, Cialis* will expand our existing portfolio in the region and strengthen Gr\u00fcnenthal’s Latin American business\u00bb, says Gabriel Baertschi, CEO, Gr\u00fcnenthal. \u00abIn 2022, we acquired Nebido*, a long-acting treatment for testosterone deficiency, and with Cialis* we can continue to serve our existing customer base and foster our growth in key Latin American markets.\u00bb<\/p>\n
\nThrough the acquisition of Cialis*, Gr\u00fcnenthal continues executing its strategy of acquiring established medicines to expand its portfolio and increase its profitability. Since 2017, Gr\u00fcnenthal has invested over \u20ac2 billion in the acquisition of established medicines, including Nebido*, the European rights to Crestor* and Nexium*, as well as the global rights to Vimovo* (excluding the U.S. and Japan), Qutenza* and Zomig* (excluding Japan). In 2023, Gr\u00fcnenthal established Gr\u00fcnenthal Meds, a joint venture with Kyowa Kirin International, which manages a portfolio of 13 brands primarily focused on pain management and, in 2024, acquired the US company Valinor Pharma and the product Movantik*. <\/p>\n
\nAbout Gr\u00fcnenthal<\/p>\n
\nGr\u00fcnenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better \u2013 and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain.<\/p>\n
\nGr\u00fcnenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2024, Gr\u00fcnenthal employed around 4,300 people and achieved revenues of \u20ac1.8 billion.<\/p>\n
\nMore information: www.grunenthal.com <\/p>\n
\nFollow us on:<\/p>\n
\nLinkedIn: Grunenthal Group <\/p>\n
\nInstagram: grunenthal<\/p>\n
\nFor further information, please contact:<\/p>\n
\nMaren Thurow<\/p>\n
\nHead Global Communication<\/p>\n
\nGr\u00fcnenthal GmbH<\/p>\n
\n52099 Aachen<\/p>\n
\nE-Mail: Maren.Thurow@grunenthal.com<\/p>\n
\nPhone: +44 7917 196855<\/p>\n","protected":false},"excerpt":{"rendered":"
(Informaci\u00f3n remitida por la empresa firmante) \u2022 Gr\u00fcnenthal announces that it agreed to acquire the commercial rights to Cialis* from Eli Lilly and Company in Mexico, Brazil and Colombia, further strengthening Gr\u00fcnenthal’s footprint in Latin America. \u2022 As part of the acquisition, Gr\u00fcnenthal will transfer the manufacturing of Cialis* to its production site in Chile. […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-61821","post","type-post","status-publish","format-standard","hentry","category-noticias"],"_links":{"self":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts\/61821","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=61821"}],"version-history":[{"count":0,"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts\/61821\/revisions"}],"wp:attachment":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=61821"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=61821"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=61821"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}